WX-081 Publication 2022

Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis
Rong Yao,a,b Bin Wang,a,b Lei Fu,a,b Lei Li,c Kejun You,c Yong-Guo Li,c Yu Lua,b
a Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
b Beijing Chest Hospital, Capital Medical University, Beijing, China
c Shanghai Jiatan Biotech Ltd., a subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China